- Home
- PALI vs POAI Comparison
PALI vs POAI Comparison
Compare PALI & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PALI
- POAI
- Stock Information
- Founded
- PALI 1996
- POAI 2002
- Country
- PALI United States
- POAI United States
- Employees
- PALI N/A
- POAI N/A
- Industry
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- POAI Industrial Specialties
- Sector
- PALI Health Care
- POAI Health Care
- Exchange
- PALI Nasdaq
- POAI Nasdaq
- Market Cap
- PALI 7.5M
- POAI 7.8M
- IPO Year
- PALI N/A
- POAI N/A
- Fundamental
- Price
- PALI $0.75
- POAI $0.95
- Analyst Decision
- PALI Strong Buy
- POAI Hold
- Analyst Count
- PALI 2
- POAI 1
- Target Price
- PALI $12.00
- POAI N/A
- AVG Volume (30 Days)
- PALI 5.4M
- POAI 187.3K
- Earning Date
- PALI 08-11-2025
- POAI 08-13-2025
- Dividend Yield
- PALI N/A
- POAI N/A
- EPS Growth
- PALI N/A
- POAI N/A
- EPS
- PALI N/A
- POAI N/A
- Revenue
- PALI N/A
- POAI $1,664,696.00
- Revenue This Year
- PALI N/A
- POAI $486.27
- Revenue Next Year
- PALI N/A
- POAI $65.50
- P/E Ratio
- PALI N/A
- POAI N/A
- Revenue Growth
- PALI N/A
- POAI 71.65
- 52 Week Low
- PALI $0.60
- POAI $0.55
- 52 Week High
- PALI $4.32
- POAI $3.06
- Technical
- Relative Strength Index (RSI)
- PALI 42.17
- POAI 69.07
- Support Level
- PALI $0.70
- POAI $0.82
- Resistance Level
- PALI $0.85
- POAI $0.96
- Average True Range (ATR)
- PALI 0.14
- POAI 0.07
- MACD
- PALI -0.02
- POAI 0.02
- Stochastic Oscillator
- PALI 7.58
- POAI 96.00
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.